Provided by Tiger Trade Technology Pte. Ltd.

Jade Biosciences

17.89
-1.2500-6.53%
Post-market: 17.890.00000.00%19:30 EDT
Volume:1.25M
Turnover:23.06M
Market Cap:1.14B
PE:-7.63
High:20.10
Open:19.38
Low:17.53
Close:19.14
52wk High:28.00
52wk Low:6.91
Shares:63.60M
Float Shares:47.12M
Volume Ratio:1.13
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3433
EPS(LYR):-3.1931
ROE:-89.18%
ROA:-33.59%
PB:0.39
PE(LYR):-5.60

Loading ...

Jade Biosciences (JBIO) Joins Growth Indexes, Is The Stock Still Undervalued?

Simply Wall St.
·
Jul 03

Jade Biosciences - to Pay Paragon Low to Mid-single-digit Percentage Royalties on Net Sales of Licensed Products - SEC Filing

THOMSON REUTERS
·
Jul 02

Jade Biosciences - Paragon Barred from New Campaigns Targeting Licensed Target for at Least Five Years - SEC Filing

THOMSON REUTERS
·
Jul 02

Jade Biosciences - to Pay up to $22 Mln in Milestone Payments to Paragon - SEC Filing

THOMSON REUTERS
·
Jul 02

Jade Biosciences - Enters Exclusive Worldwide License Agreement with Paragon Therapeutics - SEC Filing

THOMSON REUTERS
·
Jul 02

Jade Biosciences Secures Exclusive Antibody License Agreement

TIPRANKS
·
Jul 02

Jade Biosciences Licenses Paragon Antibody Program, with up to $22 Million in Milestones

Reuters
·
Jul 02

Jade Biosciences Director Mark Eisner Files Initial Beneficial Ownership Statement

Reuters
·
Jun 27

Jade Biosciences Announces Appointment of Mark Eisner, M.d., M.p.h., to Board of Directors

THOMSON REUTERS
·
Jun 26

Press Release: Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.p.h., to Board of Directors

Dow Jones
·
Jun 26

Jade Biosciences Inc : UBS Initiates Coverage With Buy Rating and Target Price $45

THOMSON REUTERS
·
Jun 15

Jade Biosciences Initiated at Buy by UBS

Dow Jones
·
Jun 15

Jade Biosciences initiated with a Buy at UBS

TIPRANKS
·
Jun 15

Jade Biosciences Shareholders Approve Governance and Audit Measures

TIPRANKS
·
Jun 12

Jade Biosciences updates bylaws to allow virtual meetings, drops pre-meeting voter list requirement

Reuters
·
Jun 12

Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)

TIPRANKS
·
Jun 06

Jade Biosciences Closes Public Offering of Shares

MT Newswires Live
·
Jun 06

Press Release: Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dow Jones
·
Jun 06

Jade Biosciences Launches Major Underwritten Equity Offering

TIPRANKS
·
Jun 05

Is Jade Biosciences (JBIO) Fairly Priced As Shares Swing And Losses Mount?

Simply Wall St.
·
Jun 05